Last reviewed · How we verify
GW679769 oral tablets
At a glance
| Generic name | GW679769 oral tablets |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults (PHASE1)
- Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment (PHASE1)
- A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). (PHASE1)
- Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769] (PHASE1)
- A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers (PHASE1)
- Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment (PHASE1)
- The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects (PHASE1)
- A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW679769 oral tablets CI brief — competitive landscape report
- GW679769 oral tablets updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI